Identification

Name
Erlotinib
Accession Number
DB00530  (APRD00951)
Type
Small Molecule
Groups
Approved, Investigational
Description

Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer.

Similar to gefitinib, erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. Erlotinib has recently been shown to be a potent inhibitor of JAK2V617F activity. JAK2V617F is a mutant of tyrosine kinase JAK2, is found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. The study suggests that erlotinib may be used for treatment of JAK2V617F-positive PV and other myeloproliferative disorders.

Structure
Thumb
Synonyms
  • [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
  • Erlotinib
  • OSI-774
External IDs
CP-358,774 / CP-358774 / CP358774 / R-1415
Product Ingredients
IngredientUNIICASInChI Key
Erlotinib HydrochlorideDA87705X9K183319-69-9GTTBEUCJPZQMDZ-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PMS-erlotinibTablet150 mgOralPharmascience Inc2016-07-28Not applicableCanada
PMS-erlotinibTablet100 mgOralPharmascience Inc2016-07-28Not applicableCanada
TarcevaTablet25 mg/1OralPhysicians Total Care, Inc.2005-07-01Not applicableUs
TarcevaTablet100 mg/1OralGenentech, Inc.2005-04-30Not applicableUs
TarcevaTablet100 mgOralHoffmann La Roche2005-07-19Not applicableCanada
TarcevaTablet100 mg/1OralPhysicians Total Care, Inc.2005-11-21Not applicableUs
TarcevaTablet, film coated100 mgOralRoche Registration Limited2005-09-19Not applicableEu
TarcevaTablet25 mgOralHoffmann La Roche2007-01-05Not applicableCanada
TarcevaTablet25 mg/1OralGenentech, Inc.2005-04-30Not applicableUs
TarcevaTablet150 mg/1OralPhysicians Total Care, Inc.2005-10-13Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-erlotinibTablet25 mgOralApotex Corporation2017-08-22Not applicableCanada
Apo-erlotinibTablet150 mgOralApotex Corporation2017-08-22Not applicableCanada
Apo-erlotinibTablet100 mgOralApotex Corporation2017-08-22Not applicableCanada
Categories
UNII
J4T82NDH7E
CAS number
183321-74-6
Weight
Average: 393.4357
Monoisotopic: 393.168856239
Chemical Formula
C22H23N3O4
InChI Key
AAKJLRGGTJKAMG-UHFFFAOYSA-N
InChI
InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)
IUPAC Name
N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
SMILES
COCCOC1=C(OCCOC)C=C2C(NC3=CC=CC(=C3)C#C)=NC=NC2=C1

Pharmacology

Indication

For the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Structured Indications
Pharmacodynamics
Not Available
Mechanism of action

The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.

TargetActionsOrganism
AEpidermal growth factor receptor
antagonist
Human
ANuclear receptor subfamily 1 group I member 2
agonist
Human
Absorption

Erlotinib is about 60% absorbed after oral administration and its bioavailability is substantially increased by food to almost 100%. Peak plasma levels occur 4 hours after dosing. The solubility of erlotinib is pH dependent. Solubility decreases pH increases. Smoking also decrease the exposure of erlotinib.

Volume of distribution

Apparent volume of distribution = 232 L

Protein binding

93% protein bound to albumin and alpha-1 acid glycoprotein (AAG)

Metabolism

Metabolism occurs in the liver. In vitro assays of cytochrome P450 metabolism showed that erlotinib is metabolized primarily by CYP3A4 and to a lesser extent by CYP1A2, and the extrahepatic isoform CYP1A1.

Route of elimination

Following a 100 mg oral dose, 91% of the dose was recovered in which 83% was in feces (1% of the dose as unchanged parent compound) and 8% in urine (0.3% of the dose as unchanged parent compound).

Half life

Median half-life of 36.2 hours.

Clearance

Smokers have a 24% higher rate of erlotinib clearance.

Toxicity

Symptoms of overdose include diarrhea, rash, and liver transaminase elevation. The most common adverse reactions (>50%) in NSCLC are rash, diarrhea, anorexia and fatigue. The most common adverse reactions (>50%) in pancreatic cancer are fatigue, rash, nausea and anorexia.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Erlotinib Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Epidermal growth factor receptorG719A/C(T;T) / (G;T) / (A;A) / (A;G) / (C;C) / (C;G)G > A or C or TEffect Directly StudiedThe presence of this polymorphism in EGFR is associated with a higher response rate to erlotinib.Details
Epidermal growth factor receptorL861Q(A;A) / (A;T) / (G;G) / (G;T)T > A or GEffect Directly StudiedThe presence of this polymorphism in EGFR is associated with a higher response rate to erlotinib.Details
Epidermal growth factor receptorL858R(G;G) / (G;T)T > GEffect Directly StudiedThe presence of this polymorphism in EGFR is associated with a higher response rate to erlotinib.Details

Interactions

Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Erlotinib can be increased when it is combined with Abiraterone.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Erlotinib.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Erlotinib.Experimental
AlmasilateThe serum concentration of Erlotinib can be decreased when it is combined with Almasilate.Approved, Experimental
AloglutamolThe serum concentration of Erlotinib can be decreased when it is combined with Aloglutamol.Experimental
AluminiumThe serum concentration of Erlotinib can be decreased when it is combined with Aluminium.Approved
Aluminium acetoacetateThe serum concentration of Erlotinib can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Erlotinib can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Erlotinib can be decreased when it is combined with Aluminum hydroxide.Approved
AmiodaroneThe serum concentration of Erlotinib can be increased when it is combined with Amiodarone.Approved, Investigational
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Erlotinib.Approved, Investigational
AprepitantThe serum concentration of Erlotinib can be increased when it is combined with Aprepitant.Approved, Investigational
ArtemetherThe metabolism of Erlotinib can be decreased when combined with Artemether.Approved
AsenapineThe serum concentration of Erlotinib can be decreased when it is combined with Asenapine.Approved
AtazanavirThe serum concentration of Erlotinib can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Erlotinib can be decreased when combined with Atomoxetine.Approved
AzithromycinThe metabolism of Erlotinib can be decreased when combined with Azithromycin.Approved
BetaxololThe metabolism of Erlotinib can be decreased when combined with Betaxolol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Erlotinib.Approved, Investigational
Bismuth SubcitrateThe serum concentration of Erlotinib can be decreased when it is combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe serum concentration of Erlotinib can be decreased when it is combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Erlotinib can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Erlotinib can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Erlotinib can be decreased when it is combined with Bosentan.Approved, Investigational
BupropionThe metabolism of Erlotinib can be decreased when combined with Bupropion.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Erlotinib.Approved
CaffeineThe metabolism of Erlotinib can be decreased when combined with Caffeine.Approved
Calcium CarbonateThe serum concentration of Erlotinib can be decreased when it is combined with Calcium Carbonate.Approved
Calcium silicateThe serum concentration of Erlotinib can be decreased when it is combined with Calcium silicate.Experimental
CarbamazepineThe serum concentration of Erlotinib can be decreased when it is combined with Carbamazepine.Approved, Investigational
CelecoxibThe metabolism of Erlotinib can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Erlotinib can be increased when it is combined with Ceritinib.Approved
ChloroquineThe metabolism of Erlotinib can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe metabolism of Erlotinib can be decreased when combined with Chlorpromazine.Approved, Vet Approved
CholecalciferolThe metabolism of Erlotinib can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe serum concentration of Erlotinib can be decreased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Erlotinib can be decreased when combined with Cinacalcet.Approved
CiprofloxacinThe serum concentration of Erlotinib can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe metabolism of Erlotinib can be decreased when combined with Citalopram.Approved
ClarithromycinThe serum concentration of Erlotinib can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Erlotinib can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Erlotinib can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineThe metabolism of Erlotinib can be decreased when combined with Clomipramine.Approved, Vet Approved
ClotrimazoleThe metabolism of Erlotinib can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Erlotinib can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Erlotinib can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Erlotinib can be decreased when combined with Cocaine.Approved, Illicit
ConivaptanThe serum concentration of Erlotinib can be increased when it is combined with Conivaptan.Approved, Investigational
CrisaboroleThe metabolism of Erlotinib can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Erlotinib can be decreased when combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Erlotinib.Approved, Investigational
CyclosporineThe metabolism of Erlotinib can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Erlotinib.Experimental
Cyproterone acetateThe serum concentration of Erlotinib can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Erlotinib can be decreased when it is combined with Dabrafenib.Approved
DarifenacinThe metabolism of Erlotinib can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Erlotinib can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Erlotinib can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Erlotinib can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Erlotinib can be decreased when combined with Delavirdine.Approved
DesipramineThe metabolism of Erlotinib can be decreased when combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Erlotinib.Approved
DexlansoprazoleThe serum concentration of Erlotinib can be decreased when it is combined with Dexlansoprazole.Approved
DexrabeprazoleThe serum concentration of Erlotinib can be decreased when it is combined with Dexrabeprazole.Experimental
DigitoxinDigitoxin may decrease the cardiotoxic activities of Erlotinib.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Erlotinib.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Erlotinib.Approved
DihydroergotamineThe metabolism of Erlotinib can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Erlotinib can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Erlotinib can be decreased when combined with Diphenhydramine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Erlotinib.Approved, Investigational
DosulepinThe metabolism of Erlotinib can be decreased when combined with Dosulepin.Approved
DoxepinThe serum concentration of Erlotinib can be decreased when it is combined with Doxepin.Approved
DoxycyclineThe metabolism of Erlotinib can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Erlotinib can be decreased when combined with Dronedarone.Approved
DuloxetineThe metabolism of Erlotinib can be decreased when combined with Duloxetine.Approved
EfavirenzThe metabolism of Erlotinib can be decreased when combined with Efavirenz.Approved, Investigational
EliglustatThe metabolism of Erlotinib can be decreased when combined with Eliglustat.Approved
EnzalutamideThe serum concentration of Erlotinib can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Erlotinib can be decreased when it is combined with Epinastine.Approved, Investigational
ErythromycinThe metabolism of Erlotinib can be decreased when combined with Erythromycin.Approved, Vet Approved
EsomeprazoleThe serum concentration of Erlotinib can be decreased when it is combined with Esomeprazole.Approved, Investigational
FamotidineThe serum concentration of Erlotinib can be decreased when it is combined with Famotidine.Approved
FelodipineThe metabolism of Erlotinib can be decreased when combined with Felodipine.Approved, Investigational
FluconazoleThe metabolism of Erlotinib can be decreased when combined with Fluconazole.Approved
FluoxetineThe metabolism of Erlotinib can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluvoxamineThe serum concentration of Erlotinib can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Erlotinib can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Erlotinib can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Erlotinib can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Erlotinib can be increased when it is combined with Fusidic Acid.Approved
GitoformateGitoformate may decrease the cardiotoxic activities of Erlotinib.Experimental
HaloperidolThe metabolism of Erlotinib can be decreased when combined with Haloperidol.Approved
HydrotalciteThe serum concentration of Erlotinib can be decreased when it is combined with Hydrotalcite.Experimental, Investigational
IdelalisibThe serum concentration of Erlotinib can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Erlotinib can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Erlotinib can be decreased when combined with Imipramine.Approved
IndinavirThe serum concentration of Erlotinib can be increased when it is combined with Indinavir.Approved
IrbesartanThe metabolism of Erlotinib can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of SN-38 an active metabolite of Irinotecan can be increased when used in combination with Erlotinib.Approved, Investigational
IsavuconazoniumThe metabolism of Erlotinib can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Erlotinib can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Erlotinib can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Erlotinib can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Erlotinib can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe serum concentration of Erlotinib can be increased when it is combined with Ketoconazole.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Erlotinib.Experimental
LansoprazoleThe serum concentration of Erlotinib can be decreased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe metabolism of Erlotinib can be decreased when combined with Lapatinib.Approved, Investigational
LidocaineThe metabolism of Erlotinib can be decreased when combined with Lidocaine.Approved, Vet Approved
LobeglitazoneThe metabolism of Erlotinib can be decreased when combined with Lobeglitazone.Approved, Investigational
LopinavirThe serum concentration of Erlotinib can be increased when it is combined with Lopinavir.Approved
LorcaserinThe metabolism of Erlotinib can be decreased when combined with Lorcaserin.Approved
LosartanThe metabolism of Erlotinib can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Erlotinib can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Erlotinib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Erlotinib can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Erlotinib can be decreased when combined with Lumefantrine.Approved
MagaldrateThe serum concentration of Erlotinib can be decreased when it is combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe serum concentration of Erlotinib can be decreased when it is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe serum concentration of Erlotinib can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Erlotinib can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium silicateThe serum concentration of Erlotinib can be decreased when it is combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe serum concentration of Erlotinib can be decreased when it is combined with Magnesium Trisilicate.Approved
ManidipineThe metabolism of Erlotinib can be decreased when combined with Manidipine.Approved, Investigational
MethadoneThe metabolism of Erlotinib can be decreased when combined with Methadone.Approved
MethanthelineThe serum concentration of Erlotinib can be decreased when it is combined with Methantheline.Approved, Investigational
MethotrimeprazineThe metabolism of Erlotinib can be decreased when combined with Methotrimeprazine.Approved
MetiamideThe serum concentration of Erlotinib can be decreased when it is combined with Metiamide.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Erlotinib.Experimental
MetoprololThe metabolism of Erlotinib can be decreased when combined with Metoprolol.Approved, Investigational
MexiletineThe metabolism of Erlotinib can be decreased when combined with Mexiletine.Approved
MidostaurinThe metabolism of Erlotinib can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Erlotinib can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe metabolism of Erlotinib can be decreased when combined with Mirabegron.Approved
MitotaneThe serum concentration of Erlotinib can be decreased when it is combined with Mitotane.Approved
NefazodoneThe serum concentration of Erlotinib can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Erlotinib can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Erlotinib can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Erlotinib can be decreased when it is combined with Nevirapine.Approved
NicardipineThe metabolism of Erlotinib can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Erlotinib can be decreased when combined with Nilotinib.Approved, Investigational
NizatidineThe serum concentration of Erlotinib can be decreased when it is combined with Nizatidine.Approved
OlanzapineThe serum concentration of Erlotinib can be decreased when it is combined with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Erlotinib can be decreased when combined with Olaparib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Erlotinib.Experimental, Investigational
OmeprazoleThe serum concentration of Erlotinib can be decreased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Erlotinib can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Erlotinib.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Erlotinib.Approved, Vet Approved
PalbociclibThe serum concentration of Erlotinib can be increased when it is combined with Palbociclib.Approved
PanobinostatThe serum concentration of Erlotinib can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Erlotinib can be decreased when it is combined with Pantoprazole.Approved
ParoxetineThe metabolism of Erlotinib can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Erlotinib.Approved
Peginterferon alfa-2bThe serum concentration of Erlotinib can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentobarbitalThe serum concentration of Erlotinib can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Erlotinib.Experimental
PhenobarbitalThe serum concentration of Erlotinib can be decreased when it is combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Erlotinib can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PioglitazoneThe metabolism of Erlotinib can be decreased when combined with Pioglitazone.Approved, Investigational
PosaconazoleThe serum concentration of Erlotinib can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe serum concentration of Erlotinib can be decreased when it is combined with Primidone.Approved, Vet Approved
PromazineThe metabolism of Erlotinib can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Erlotinib can be decreased when it is combined with Promethazine.Approved
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Erlotinib.Experimental
QuinidineThe metabolism of Erlotinib can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Erlotinib can be decreased when combined with Quinine.Approved
RabeprazoleThe serum concentration of Erlotinib can be decreased when it is combined with Rabeprazole.Approved, Investigational
RanitidineThe serum concentration of Erlotinib can be decreased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Erlotinib can be increased when it is combined with Ranolazine.Approved, Investigational
RifabutinThe serum concentration of Erlotinib can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Erlotinib can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Erlotinib can be decreased when it is combined with Rifapentine.Approved
RolapitantThe metabolism of Erlotinib can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Erlotinib can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneThe metabolism of Erlotinib can be decreased when combined with Rosiglitazone.Approved, Investigational
Roxatidine acetateThe serum concentration of Erlotinib can be decreased when it is combined with Roxatidine acetate.Approved, Investigational
SaquinavirThe serum concentration of Erlotinib can be increased when it is combined with Saquinavir.Approved, Investigational
SecobarbitalThe metabolism of Erlotinib can be increased when combined with Secobarbital.Approved, Vet Approved
SertralineThe metabolism of Erlotinib can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Erlotinib can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Erlotinib can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Erlotinib can be increased when it is combined with Simeprevir.Approved
Sodium bicarbonateThe serum concentration of Erlotinib can be decreased when it is combined with Sodium bicarbonate.Approved
St. John's WortThe serum concentration of Erlotinib can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Erlotinib can be increased when it is combined with Stiripentol.Approved
SulfamethoxazoleThe metabolism of Erlotinib can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Erlotinib can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TamoxifenThe metabolism of Erlotinib can be decreased when combined with Tamoxifen.Approved
TelaprevirThe serum concentration of Erlotinib can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Erlotinib can be increased when it is combined with Telithromycin.Approved
Tenofovir disoproxilThe metabolism of Erlotinib can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerbinafineThe metabolism of Erlotinib can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe serum concentration of Erlotinib can be decreased when it is combined with Teriflunomide.Approved
TheophyllineThe metabolism of Erlotinib can be decreased when combined with Theophylline.Approved
ThioridazineThe metabolism of Erlotinib can be decreased when combined with Thioridazine.Approved, Withdrawn
TiclopidineThe metabolism of Erlotinib can be decreased when combined with Ticlopidine.Approved
TipranavirThe metabolism of Erlotinib can be decreased when combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Erlotinib can be decreased when it is combined with Tocilizumab.Approved
TopiroxostatThe metabolism of Erlotinib can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Erlotinib.Approved, Investigational
TranylcypromineThe metabolism of Erlotinib can be decreased when combined with Tranylcypromine.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Erlotinib.Approved, Investigational
TrimethoprimThe metabolism of Erlotinib can be decreased when combined with Trimethoprim.Approved, Vet Approved
TromethamineThe serum concentration of Erlotinib can be decreased when it is combined with Tromethamine.Approved
VenlafaxineThe metabolism of Erlotinib can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Erlotinib can be decreased when combined with Verapamil.Approved
VoriconazoleThe serum concentration of Erlotinib can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Erlotinib.Approved
ZiprasidoneThe metabolism of Erlotinib can be decreased when combined with Ziprasidone.Approved
ZucapsaicinThe metabolism of Erlotinib can be decreased when combined with Zucapsaicin.Approved
Food Interactions
  • Take at least 1 hour before or 2 hours after any food.
  • Take with a glass of water.

References

Synthesis Reference
US5747498
General References
  1. Raymond E, Faivre S, Armand JP: Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs. 2000;60 Suppl 1:15-23; discussion 41-2. [PubMed:11129168]
  2. Li Z, Xu M, Xing S, Ho WT, Ishii T, Li Q, Fu X, Zhao ZJ: Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem. 2007 Feb 9;282(6):3428-32. Epub 2006 Dec 18. [PubMed:17178722]
  3. Dudek AZ, Kmak KL, Koopmeiners J, Keshtgarpour M: Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer. 2006 Jan;51(1):89-96. Epub 2005 Nov 14. [PubMed:16290256]
  4. Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE, Nicholson RI: Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer. 2004 Dec;11(4):793-814. [PubMed:15613453]
  5. Blum G, Gazit A, Levitzki A: Substrate competitive inhibitors of IGF-1 receptor kinase. Biochemistry. 2000 Dec 26;39(51):15705-12. [PubMed:11123895]
External Links
Human Metabolome Database
HMDB14671
KEGG Drug
D07907
PubChem Compound
176870
PubChem Substance
46508021
ChemSpider
154044
BindingDB
5446
ChEBI
114785
ChEMBL
CHEMBL553
Therapeutic Targets Database
DAP001010
PharmGKB
PA134687924
HET
AQ4
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Erlotinib
ATC Codes
L01XE03 — Erlotinib
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
PDB Entries
1m17 / 4hjo
FDA label
Download (999 KB)
MSDS
Download (107 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentHead and Neck Carcinoma1
0CompletedTreatmentHead and Neck Carcinoma / Pharynx Cancer1
0WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1Active Not RecruitingDiagnosticCancers / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1Active Not RecruitingPreventionCancer of Head and Neck / Neoplasms, Head and Neck1
1Active Not RecruitingPreventionHead and Neck Carcinoma1
1Active Not RecruitingTreatmentAdult Solid Neoplasm1
1Active Not RecruitingTreatmentAdult Solid Neoplasm / Pancreatic Acinar Cell Carcinoma / Pancreatic Ductal Adenocarcinoma / Recurrent Pancreatic Carcinoma / Stage IV Pancreatic Cancer / Stage IV Pancreatic Cancer AJCC v6 and v71
1Active Not RecruitingTreatmentCancer, Advanced1
1Active Not RecruitingTreatmentCancer, Advanced / Tumors, Solid1
1Active Not RecruitingTreatmentCancer, Breast / Colon Neoplasms / Lung Cancers / Malignant Neoplasm of Colon / Melanoma / Neoplasms, Breast / Renal Cancers1
1Active Not RecruitingTreatmentEGFR-Mutant Lung Cancer1
1Active Not RecruitingTreatmentHead and Neck Carcinoma1
1Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
1Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Squamous Non-Small Cell Lung Cancer1
1Active Not RecruitingTreatmentPancreatic Adenocarcinoma Metastatic / Recurrent Pancreatic Carcinoma / Stage III Pancreatic Cancer / Stage III Pancreatic Cancer AJCC v6 and v7 / Stage IV Pancreatic Cancer / Stage IV Pancreatic Cancer AJCC v6 and v71
1Active Not RecruitingTreatmentSolid Neoplasms1
1CompletedPreventionChemoprevention / Cholangiocarcinomas / Primary Sclerosing Cholangitis (PSC) / Trisomy 71
1CompletedTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Advanced Adult Primary Liver Cancer / Carcinoma of the Appendix / Gastrointestinal Stromal Tumors / Metastatic Gastrointestinal Carcinoid Tumor / Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Adenoid Cystic Carcinoma of the Oral Cavity / Recurrent Adult Primary Liver Cancer / Recurrent Anal Cancer / Recurrent Basal Cell Carcinoma of the Lip / Recurrent Colon Cancer / Recurrent Esophageal Cancer / Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Recurrent Extrahepatic Bile Duct Cancer / Recurrent Gallbladder Cancer / Recurrent Gastric Cancer / Recurrent Gastrointestinal Carcinoid Tumor / Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Recurrent Lymphoepithelioma of the Nasopharynx / Recurrent Lymphoepithelioma of the Oropharynx / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Recurrent Mucoepidermoid Carcinoma of the Oral Cavity / Recurrent Non-small Cell Lung Cancer / Recurrent Pancreatic Cancer / Recurrent Rectal Cancer / Recurrent Salivary Gland Cancer / Recurrent Small Intestine Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Small Intestine Adenocarcinoma / Small Intestine Leiomyosarcoma / Small Intestine Lymphoma / Stage IV Adenoid Cystic Carcinoma of the Oral Cavity / Stage IV Anal Cancer / Stage IV Basal Cell Carcinoma of the Lip / Stage IV Colon Cancer / Stage IV Esophageal Cancer / Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Stage IV Gastric Cancer / Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Stage IV Lymphoepithelioma of the Nasopharynx / Stage IV Lymphoepithelioma of the Oropharynx / Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Stage IV Mucoepidermoid Carcinoma of the Oral Cavity / Stage IV Non-Small Cell Lung Cancer / Stage IV Pancreatic Cancer / Stage IV Rectal Cancer / Stage IV Salivary Gland Cancer / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IV Verrucous Carcinoma of the Larynx / Stage IV Verrucous Carcinoma of the Oral Cavity / Tongue Cancer / Unresectable Extrahepatic Bile Duct Cancer / Unresectable Gallbladder Cancer1
1CompletedTreatmentAdenocarcinoma of the Esophagus / Adenocarcinoma of the Stomach / Adenocarcinomas of the Gastroesophageal Junction / Squamous Cell Carcinoma of the Esophagus / Stage II Esophageal Cancer / Stage II Gastric Cancer / Stage III Esophageal Cancer / Stage III Gastric Cancer1
1CompletedTreatmentAdenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer1
1CompletedTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Ependymoma / Adult Anaplastic Oligodendroglioma / Adult Brain Stem Glioma / Adult Diffuse Astrocytoma / Adult Ependymoblastoma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Mixed Glioma / Adult Myxopapillary Ependymoma / Adult Oligodendroglioma / Adult Pilocytic Astrocytoma / Adult Primary Hepatocellular Carcinoma / Adult Subependymoma / Advanced Adult Primary Liver Cancer / Advanced Malignant Mesothelioma / Male Breast Cancer / Recurrent Adenoid Cystic Carcinoma of the Oral Cavity / Recurrent Adult Brain Tumor / Recurrent Adult Primary Liver Cancer / Recurrent Anal Cancer / Recurrent Basal Cell Carcinoma of the Lip / Recurrent Bladder Cancer / Recurrent Breast Cancer / Recurrent Cervical Cancer / Recurrent Colon Cancer / Recurrent Esophageal Cancer / Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Recurrent Lymphoepithelioma of the Nasopharynx / Recurrent Lymphoepithelioma of the Oropharynx / Recurrent Malignant Mesothelioma / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Recurrent Mucoepidermoid Carcinoma of the Oral Cavity / Recurrent Non-small Cell Lung Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Pancreatic Cancer / Recurrent Prostate Cancer / Recurrent Rectal Cancer / Recurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Stage II Esophageal Cancer / Stage II Pancreatic Cancer / Stage III Esophageal Cancer / Stage III Pancreatic Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Adenoid Cystic Carcinoma of the Oral Cavity / Stage IV Anal Cancer / Stage IV Basal Cell Carcinoma of the Lip / Stage IV Bladder Cancer / Stage IV Breast Cancer / Stage IV Colon Cancer / Stage IV Esophageal Cancer / Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Stage IV Lymphoepithelioma of the Nasopharynx / Stage IV Lymphoepithelioma of the Oropharynx / Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Stage IV Mucoepidermoid Carcinoma of the Oral Cavity / Stage IV Non-Small Cell Lung Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Pancreatic Cancer / Stage IV Prostate Cancer / Stage IV Rectal Cancer / Stage IV Salivary Gland Cancer / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IV Verrucous Carcinoma of the Larynx / Stage IV Verrucous Carcinoma of the Oral Cavity / Stage IVA Cervical Cancer / Stage IVB Cervical Cancer / Unspecified Adult Solid Tumor, Protocol Specific / Untreated Metastatic Squamous Neck Cancer With Occult Primary1
1CompletedTreatmentAdult Primary Hepatocellular Carcinoma / Advanced Adult Primary Liver Cancer / Localized Unresectable Adult Primary Liver Cancer / Recurrent Adult Primary Liver Cancer1
1CompletedTreatmentAdvanced Cancers2
1CompletedTreatmentAdvanced Cancers / Tumors, Solid1
1CompletedTreatmentAdvanced Malignant Solid Tumors1
1CompletedTreatmentAdvanced Pancreatic Cancer1
1CompletedTreatmentAdvanced Solid Tumor Malignancies1
1CompletedTreatmentAdvanced Solid Tumors5
1CompletedTreatmentAdvanced Solid Tumours / Cancers / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1CompletedTreatmentAdvanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)1
1CompletedTreatmentAdvanced/Recurrent Non-small-cell Lung Cancer1
1CompletedTreatmentBrain Stem Gliomas / Malignant Brain Tumors1
1CompletedTreatmentBrain and Central Nervous System Tumors1
1CompletedTreatmentCancer of Parotid / Head and Neck Carcinoma / Malignant Neoplasm of Thyroid / Melanoma / Parotid Gland Cancer / Stage IV Head and Neck Cancer / Thyroid neoplasms malignant1
1CompletedTreatmentCancer, Advanced3
1CompletedTreatmentCancer, Breast2
1CompletedTreatmentCancer, Breast / Estrogen Receptor Breast Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
1CompletedTreatmentCancers3
1CompletedTreatmentCancers / Lung Cancer Non-Small Cell Cancer (NSCLC)2
1CompletedTreatmentColorectal Cancers2
1CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer / Malignant Neoplasm of Pancreas / Periampullary Adenocarcinoma / Small Intestine Cancer1
1CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer / Malignant Neoplasm of Pancreas1
1CompletedTreatmentGlioblastomas / Gliosarcoma1
1CompletedTreatmentHead and Neck Carcinoma2
1CompletedTreatmentHead and Neck Carcinoma / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1CompletedTreatmentHead and Neck Carcinoma / Lung Cancers1
1CompletedTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
1CompletedTreatmentLocally Advanced, Metastatic Solid Tumors1
1CompletedTreatmentLow-Grade Gliomas1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)10
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Lymphomas / Tumors, Solid1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Metastatic Brain Tumors1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Squamous Cell Carcinoma (SCC)1
1CompletedTreatmentLung Cancers1
1CompletedTreatmentMalignant Diseases1
1CompletedTreatmentMalignant Lymphomas / Malignant Solid Tumours / Multiple Myeloma (MM)1
1CompletedTreatmentMalignant Neoplasm of Pancreas5
1CompletedTreatmentMalignant Neoplasm of Pancreas / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentMetastatic Pancreatic Carcinoma1
1CompletedTreatmentMetastatic Solid Tumors1
1CompletedTreatmentMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Stage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Verrucous Carcinoma of the Larynx / Stage III Verrucous Carcinoma of the Oral Cavity / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Verrucous Carcinoma of the Larynx / Stage IVB Verrucous Carcinoma of the Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Larynx / Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Oropharynx / Stage IVC Verrucous Carcinoma of the Larynx / Stage IVC Verrucous Carcinoma of the Oral Cavity / Tongue Cancer / Untreated Metastatic Squamous Neck Cancer With Occult Primary1
1CompletedTreatmentMucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage IIIA Colon Cancer / Stage IIIA Rectal Cancer / Stage IIIB Colon Cancer / Stage IIIB Rectal Cancer / Stage IIIC Colon Cancer / Stage IIIC Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
1CompletedTreatmentNeoplasms2
1CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer, Solid Cancers1
1CompletedTreatmentPancreatic Cancer Metastatic1
1CompletedTreatmentPancreatic Cancer Metastatic / Pancreatic Carcinoma Non-resectable1
1CompletedTreatmentPreviously Treated Childhood Rhabdomyosarcoma / Recurrent Childhood Brain Tumor / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Malignant Germ Cell Tumor / Recurrent Childhood Medulloblastoma / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Soft Tissue Sarcoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Neuroblastoma / Recurrent Osteosarcoma1
1CompletedTreatmentRectal Carcinoma1
1CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer2
1CompletedTreatmentRefractory Solid Tumors1
1CompletedTreatmentStage II Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage II Squamous Cell Carcinoma of the Oropharynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Oropharynx1
1CompletedTreatmentTriple Negative Breast Cancer (TNBC)1
1CompletedTreatmentTumors, Solid3
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific4
1RecruitingNot AvailableLung Cancers1
1RecruitingTreatmentAdvanced Solid Malignancies / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1RecruitingTreatmentAdvanced Solid Tumors / Cancers1
1RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
1RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
1RecruitingTreatmentMalignant Neoplasm of Pancreas1
1RecruitingTreatmentRecurrent Non-small Cell Lung Cancer1
1RecruitingTreatmentTumors, Solid1
1TerminatedPreventionDysplasia / Metaplasia / Pulmonary Precancerous Condition1
1TerminatedTreatmentAdenocarcinoma of the Lung / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
1TerminatedTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Oligodendroglioma / Adult Diffuse Astrocytoma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Mixed Glioma / Adult Oligodendroglioma / Recurrent Adult Brain Tumor1
1TerminatedTreatmentAdvanced Malignancies, Non-small Cell Lung Cancer1
1TerminatedTreatmentBrain and Central Nervous System Tumors1
1TerminatedTreatmentEGFR Mutated EGFR TKI Naive Metastatic NSCLC1
1TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Recurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
1TerminatedTreatmentNeoplasm Metastases / Neuroendocrine Tumors / Non-Small Cell Lung Carcinoma (NSCLC) / Renal Cell Adenocarcinoma1
1TerminatedTreatmentNeoplasms1
1TerminatedTreatmentNon-small Cell Lung Cancer (NSCLC), Recurrent / Non-small Cell Lung Cancer (NSCLC), Stage IV / Recurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1TerminatedTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IV Non-Small Cell Lung Cancer1
1Unknown StatusTreatmentAdvanced Solid Tumors1
1Unknown StatusTreatmentBrain and Central Nervous System Tumors1
1Unknown StatusTreatmentEsophageal Cancers / Precancerous Conditions1
1Unknown StatusTreatmentMalignant Neoplasm of Pancreas1
1WithdrawnTreatmentAdvanced Cancers1
1WithdrawnTreatmentCervical Cancers1
1WithdrawnTreatmentLung Cancers / Metastatic Cancers1
1WithdrawnTreatmentRecurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Salivary Gland Squamous Cell Carcinoma / Tongue Cancer1
1WithdrawnTreatmentTumors, Solid1
1, 2Active Not RecruitingTreatmentAdenocarcinoma of the Lung / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2Active Not RecruitingTreatmentAdenocarcinoma of the Pancreas / Malignant Neoplasm of Pancreas1
1, 2Active Not RecruitingTreatmentLung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2Active Not RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1, 2CompletedDiagnosticPrecancerous Conditions1
1, 2CompletedTreatmentAdenocarcinoma of the Rectum / Rectal Carcinoma1
1, 2CompletedTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Oligodendroglioma / Adult Diffuse Astrocytoma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Mixed Glioma / Adult Pilocytic Astrocytoma / Adult Pineal Gland Astrocytoma / Adult Subependymal Giant Cell Astrocytoma / Recurrent Adult Brain Tumor1
1, 2CompletedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor1
1, 2CompletedTreatmentAnaplastic Astrocytoma (AA) / Glioblastoma Multiforme1
1, 2CompletedTreatmentBrain and Central Nervous System Tumors1
1, 2CompletedTreatmentCancer, Breast2
1, 2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
1, 2CompletedTreatmentClear Cell Renal Cell Carcinoma1
1, 2CompletedTreatmentColorectal Cancers1
1, 2CompletedTreatmentHead and Neck Carcinoma1
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)5
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Solid Tumours1
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Small Cell Lung Carcinoma (NSCLC)1
1, 2CompletedTreatmentLung Cancers4
1, 2CompletedTreatmentLung Cancers / Metastatic Cancers1
1, 2CompletedTreatmentLung Cancers / Unspecified Adult Solid Tumor, Protocol Specific2
1, 2CompletedTreatmentMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Recurrent Adenoid Cystic Carcinoma of the Oral Cavity / Recurrent Basal Cell Carcinoma of the Lip / Recurrent Colon Cancer / Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Recurrent Lymphoepithelioma of the Nasopharynx / Recurrent Lymphoepithelioma of the Oropharynx / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Recurrent Mucoepidermoid Carcinoma of the Oral Cavity / Recurrent Non-small Cell Lung Cancer / Recurrent Pancreatic Cancer / Recurrent Rectal Cancer / Recurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Stage III Adenoid Cystic Carcinoma of the Oral Cavity / Stage III Basal Cell Carcinoma of the Lip / Stage III Colon Cancer / Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Stage III Lymphoepithelioma of the Nasopharynx / Stage III Lymphoepithelioma of the Oropharynx / Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Stage III Mucoepidermoid Carcinoma of the Oral Cavity / Stage III Pancreatic Cancer / Stage III Rectal Cancer / Stage III Salivary Gland Cancer / Stage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage III Verrucous Carcinoma of the Larynx / Stage III Verrucous Carcinoma of the Oral Cavity / Stage IIIb Non-small Cell Lung Cancer / Stage IV Adenoid Cystic Carcinoma of the Oral Cavity / Stage IV Basal Cell Carcinoma of the Lip / Stage IV Colon Cancer / Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Stage IV Lymphoepithelioma of the Nasopharynx / Stage IV Lymphoepithelioma of the Oropharynx / Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Stage IV Mucoepidermoid Carcinoma of the Oral Cavity / Stage IV Non-Small Cell Lung Cancer / Stage IV Pancreatic Cancer / Stage IV Rectal Cancer / Stage IV Renal Cell Cancer / Stage IV Salivary Gland Cancer / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IV Verrucous Carcinoma of the Larynx / Stage IV Verrucous Carcinoma of the Oral Cavity / Untreated Metastatic Squamous Neck Cancer With Occult Primary1
1, 2CompletedTreatmentMyelodysplastic Syndrome1
1, 2CompletedTreatmentNSCLC (Advanced Non-small Cell Lung Cancer)1
1, 2CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Stage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Ovarian Epithelial Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IIIB Ovarian Epithelial Cancer / Stage IIIC Ovarian Epithelial Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVC Squamous Cell Carcinoma of the Larynx / Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Oropharynx1
1, 2CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1, 2CompletedTreatmentRecurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Salivary Gland Squamous Cell Carcinoma / Stage III Salivary Gland Cancer / Stage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IV Salivary Gland Cancer / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity1
1, 2CompletedTreatmentRecurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Salivary Gland Squamous Cell Carcinoma / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity1
1, 2CompletedTreatmentStage IV Pancreatic Cancer1
1, 2Not Yet RecruitingTreatmentEGFR Mutation Positive Non Small Cell Lung Cancer1
1, 2Not Yet RecruitingTreatmentEbola Virus Disease1
1, 2RecruitingTreatmentAdenocarcinoma of the Lung / Lung Cancer Metastatic / Lung Cancers / Lung carcinoma cell type unspecified stage IV / Recurrent Lung Adenocarcinoma / Recurrent Lung Cancer1
1, 2RecruitingTreatmentEGFR Activating Mutation / EGFR Exon 20 Insertion Mutation / Recurrent Non-Small Cell Lung Carcinoma / Stage IV Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer AJCC v71
1, 2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
1, 2RecruitingTreatmentLung Cancers1
1, 2RecruitingTreatmentNeoplasms, Pancreatic1
1, 2SuspendedTreatmentMetastatic Non-Small Cell Lung Cancer / Non-Small Cell Lung Cancer Recurrent1
1, 2TerminatedSupportive CareLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2TerminatedTreatmentBrain Cancer / Glioblastoma Multiforme1
1, 2TerminatedTreatmentHead and Neck Carcinoma1
1, 2TerminatedTreatmentHepatocellular,Carcinoma1
1, 2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)5
1, 2TerminatedTreatmentNeoplasms1
1, 2TerminatedTreatmentProstate Cancer1
1, 2TerminatedTreatmentRenal Cell Adenocarcinoma1
1, 2Unknown StatusTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Oligodendroglioma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Grade I Meningioma / Adult Grade II Meningioma / Adult Grade III Meningioma / Adult Mixed Glioma / Recurrent Adult Brain Tumor1
1, 2Unknown StatusTreatmentCancer of the Head / Cancer of the Larynx / Cancer of the Neck / Cancer of the Pharynx / Paranasal Sinus Neoplasms1
1, 2Unknown StatusTreatmentLung Cancers1
1, 2WithdrawnTreatmentEGFR Unknown or Wild-type / Lung Cancer Non-Small Cell Cancer (NSCLC) / Stage IV Disease1
1, 2WithdrawnTreatmentLiver Cancer1
1, 2WithdrawnTreatmentLung Cancers1
1, 2WithdrawnTreatmentPancreatic Cancer, Metastatic1
1, 2WithdrawnTreatmentRecurrent Skin Cancer / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Squamous Cell Carcinoma of the Skin / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity1
2Active Not RecruitingTreatmentAdenocarcinoma of the Lung / Adenosquamous Lung Carcinoma / Bronchioloalveolar Carcinoma / Malignant Pericardial Effusion / Malignant Pleural Effusions / Minimally Invasive Lung Adenocarcinoma / Stage IIIb Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer AJCC v7 / Stage IV Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer AJCC v71
2Active Not RecruitingTreatmentAdenocarcinoma of the Pancreas1
2Active Not RecruitingTreatmentAdenocarcinomas / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2Active Not RecruitingTreatmentBladder Cancers1
2Active Not RecruitingTreatmentBrain Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2Active Not RecruitingTreatmentBrain and Central Nervous System Tumors1
2Active Not RecruitingTreatmentCancer, Breast1
2Active Not RecruitingTreatmentCancers1
2Active Not RecruitingTreatmentColorectal Cancers1
2Active Not RecruitingTreatmentDiffuse Intrinsic Pontine Glioma (DIPG)1
2Active Not RecruitingTreatmentEGFR Activating Mutation / EGFR Exon 19 Deletion Mutation / EGFR NP_005219.2:p.L858R / Non-Squamous Non-Small Cell Lung Carcinoma / Stage IV Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer AJCC v71
2Active Not RecruitingTreatmentEstrogen Receptor-negative Breast Cancer / HER2-Negative Breast Cancer / Progesterone Receptor-negative Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer / Triple-Negative Breast Cancer (TNBC)1
2Active Not RecruitingTreatmentHead and Neck Carcinoma1
2Active Not RecruitingTreatmentHead and Neck Carcinoma / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
2Active Not RecruitingTreatmentLeukemias1
2Active Not RecruitingTreatmentLiver Cancer2
2Active Not RecruitingTreatmentLocally Advanced Non-Small Cell Lung Cancer1
2Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)7
2Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
2Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Recurrent Non-Small Cell Lung Carcinoma / Stage IV Non-Small Cell Lung Cancer1
2Active Not RecruitingTreatmentLung Cancers7
2Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas2
2Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2Active Not RecruitingTreatmentMetastatic Cancers1
2Active Not RecruitingTreatmentMetastatic Colorectal Cancers1
2Active Not RecruitingTreatmentMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Salivary Gland Squamous Cell Carcinoma / Stage IV Salivary Gland Cancer / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IV Verrucous Carcinoma of the Larynx / Stage IV Verrucous Carcinoma of the Oral Cavity / Tongue Cancer / Untreated Metastatic Squamous Neck Cancer With Occult Primary1
2Active Not RecruitingTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
2Active Not RecruitingTreatmentNon-Squamous Non-Small Cell Lung Cancer1
2Active Not RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
2Active Not RecruitingTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IV Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer AJCC v71
2Active Not RecruitingTreatmentSkin Cancers1
2Active Not RecruitingTreatmentTransitional Cell Carcinoma1
2CompletedNot AvailableLung Cancer Non-Small Cell Cancer (NSCLC)2
2CompletedPreventionAdenomatous Polyposis Coli1
2CompletedPreventionAdenomatous Polyps / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage I Colon Cancer / Stage I Rectal Cancer / Stage IIA Colon Cancer / Stage IIA Rectal Cancer / Stage IIB Colon Cancer / Stage IIB Rectal Cancer / Stage IIC Colon Cancer / Stage IIC Rectal Cancer / Stage IIIA Colon Cancer / Stage IIIA Rectal Cancer / Stage IIIB Colon Cancer / Stage IIIB Rectal Cancer / Stage IIIC Colon Cancer / Stage IIIC Rectal Cancer1
2CompletedPreventionHead and Neck Carcinoma1
2CompletedPreventionHistological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy1
2CompletedPreventionProstate Cancer1
2CompletedTreatmentAdenocarcinoma of Colon / Adenocarcinoma of Rectum / Metastatic Disease1
2CompletedTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
2CompletedTreatmentAdenocarcinoma of the Esophagus / Adenocarcinomas of the Gastroesophageal Junction / Recurrent Esophageal Cancer / Squamous Cell Carcinoma of the Esophagus / Stage III Esophageal Cancer / Stage IV Esophageal Cancer1
2CompletedTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Recurrent Non-small Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentAdenocarcinoma of the Lung / Adenosquamous Lung Carcinoma / Bronchioloalveolar Carcinoma / Large Cell Lung Carcinoma / Recurrent Non-Small Cell Lung Carcinoma / Squamous Cell Lung Carcinoma1
2CompletedTreatmentAdenocarcinoma of the Lung / Large Cell Lung Cancer / Recurrent Non-small Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentAdenocarcinoma of the Lung / Metastatic Brain Tumors1
2CompletedTreatmentAdenocarcinoma of the Pancreas / Malignant Neoplasm of Pancreas1
2CompletedTreatmentAdenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
2CompletedTreatmentAdenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
2CompletedTreatmentAdenocarcinoma, Bronchiolo-Alveolar1
2CompletedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma1
2CompletedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor1
2CompletedTreatmentAdult Primary Cholangiocellular Carcinoma / Adult Primary Hepatocellular Carcinoma / Advanced Adult Primary Liver Cancer / Cholangiocarcinoma of the Extrahepatic Bile Duct / Cholangiocarcinoma of the Gallbladder / Localized Unresectable Adult Primary Liver Cancer / Recurrent Adult Primary Liver Cancer / Recurrent Extrahepatic Bile Duct Cancer / Recurrent Gallbladder Cancer / Unresectable Extrahepatic Bile Duct Cancer / Unresectable Gallbladder Cancer1
2CompletedTreatmentAdult Primary Hepatocellular Carcinoma / Advanced Adult Primary Liver Cancer / Localized Unresectable Adult Primary Liver Cancer / Recurrent Adult Primary Liver Cancer1
2CompletedTreatmentAdvanced Malignant Mesothelioma / Epithelial Mesothelioma / Recurrent Malignant Mesothelioma / Sarcomatous Mesothelioma1
2CompletedTreatmentAdvanced Non-Small Cell Lung Cancer1
2CompletedTreatmentAdvanced Solid Tumors1
2CompletedTreatmentBladder Cancers1
2CompletedTreatmentBrain and Central Nervous System Tumors1
2CompletedTreatmentBrenner Tumor / Fallopian Tube Cancer / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Undifferentiated Adenocarcinoma / Stage III Ovarian Epithelial Cancer / Stage IV Ovarian Epithelial Cancer1
2CompletedTreatmentCNS Tumor, Adult1
2CompletedTreatmentCancer, Breast5
2CompletedTreatmentCancer, Ovarian / Clear Cell Mullerian Tumor / Fallopian Tube Cancer / Papillary Serous Mullerian Tumor / Primary Peritoneal Cancer1
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
2CompletedTreatmentCancers2
2CompletedTreatmentCancers / Pancreas1
2CompletedTreatmentCarcinoma NOS1
2CompletedTreatmentCervical Squamous Cell Carcinoma / Recurrent Cervical Cancer1
2CompletedTreatmentChildhood Renal Cell Carcinoma / Renal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer / Type 1 Papillary Renal Cell Carcinoma / Type 2 Papillary Renal Cell Carcinoma1
2CompletedTreatmentCholangiocarcinoma of the Extrahepatic Bile Duct / Cholangiocarcinoma of the Gallbladder / Gastrointestinal Cancers / Recurrent Extrahepatic Bile Duct Cancer / Recurrent Gallbladder Cancer / Unresectable Extrahepatic Bile Duct Cancer / Unresectable Gallbladder Cancer1
2CompletedTreatmentCholangiocarcinomas / Gallbladder Cancer1
2CompletedTreatmentColorectal Cancers1
2CompletedTreatmentColorectal Cancers / Neoplasms Metastasis2
2CompletedTreatmentEndometrial Cancers1
2CompletedTreatmentErlotinib / Neoadjuvant Therapy / Neoplasms, Lung1
2CompletedTreatmentEsophageal Cancers2
2CompletedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
2CompletedTreatmentExtrahepatic Bile Duct Adenocarcinoma / Gallbladder Adenocarcinoma / Gallbladder Adenocarcinoma With Squamous Metaplasia / Hilar Cholangiocarcinoma / Recurrent Extrahepatic Bile Duct Carcinoma / Recurrent Gallbladder Carcinoma / Undifferentiated Gallbladder Carcinoma / Unresectable Extrahepatic Bile Duct Carcinoma / Unresectable Gallbladder Carcinoma1
2CompletedTreatmentFallopian Tube Cancer / Primary Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer / Stage IV Ovarian Epithelial Cancer1
2CompletedTreatmentGlioblastoma Multiforme / Gliosarcoma1
2CompletedTreatmentGlioblastomas1
2CompletedTreatmentGlioblastomas / Gliosarcoma3
2CompletedTreatmentHead and Neck Carcinoma5
2CompletedTreatmentHepatocellular,Carcinoma1
2CompletedTreatmentHepatocellular,Carcinoma / Liver Cancer1
2CompletedTreatmentLeukemia, Myelomonocytic, Acute1
2CompletedTreatmentLiver Cancer1
2CompletedTreatmentLocally Advanced Non-Small Cell Lung Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentLocally Advanced Pancreatic Cancer / Pancreatic Cancer Metastatic1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)39
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasm Recurrence, Local1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms, Breast1
2CompletedTreatmentLung Cancers14
2CompletedTreatmentMalignant Neoplasm of Nasopharynx1
2CompletedTreatmentMalignant Neoplasm of Pancreas11
2CompletedTreatmentMalignant Neoplasm of Pancreas / Neoplasms Metastasis1
2CompletedTreatmentMalignant Neoplasm of Pancreas / Pancreatic Cancer Metastatic1
2CompletedTreatmentMalignant Peritoneal Mesothelioma1
2CompletedTreatmentMelanoma1
2CompletedTreatmentMesothelioma1
2CompletedTreatmentMetastases / Renal Cell Adenocarcinoma1
2CompletedTreatmentMetastatic Adenocarcinoma of Gastric Cardia / Metastatic Adenocarcinoma of the Esophagus / Unresectable Adenocarcinoma of Gastric Cardia / Unresectable Adenocarcinoma of the Esophagus1
2CompletedTreatmentMetastatic Adenocarcinoma of the Pancreas1
2CompletedTreatmentMetastatic Non-Small Cell Lung Cancer / Non-Squamous Non-Small Cell Lung Cancer1
2CompletedTreatmentMyelodysplastic Syndrome1
2CompletedTreatmentNeoplasms, Ovarian1
2CompletedTreatmentNon-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy1
2CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer12
2CompletedTreatmentPancreas Neoplasms1
2CompletedTreatmentPancreatic Cancer Metastatic2
2CompletedTreatmentProstate Cancer3
2CompletedTreatmentRecurrent Breast Carcinoma / Stage IV Breast Cancer1
2CompletedTreatmentRecurrent Non Small Cell Lung Cancer1
2CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer2
2CompletedTreatmentRecurrent Renal Cell Cancer / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer1
2CompletedTreatmentRenal Cancers3
2CompletedTreatmentRenal Cell Adenocarcinoma1
2CompletedTreatmentSarcomas1
2CompletedTreatmentSquamous Cell Carcinoma (SCC)1
2CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2CompletedTreatmentStage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx1
2CompletedTreatmentAdvanced thymic carcinoma / Thymic Cancer1
2CompletedTreatmentUnknown Primary Neoplasms2
2Enrolling by InvitationTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2Not Yet RecruitingTreatmentAdenocarcinoma of the Lung / EGFR Positive Non-small Cell Lung Cancer1
2Not Yet RecruitingTreatmentAdvanced Solid Tumors / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
2Not Yet RecruitingTreatmentColo-rectal Cancer1
2Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2Not Yet RecruitingTreatmentLung Cancers1
2RecruitingPreventionAPC Gene Mutation / Attenuated Familial Adenomatous Polyposis / Familial Adenomatous Polyposis (FAP)1
2RecruitingTreatmentAdenocarcinoma of the Lung1
2RecruitingTreatmentAdvanced Solid Tumors / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentBladder Carcinoma / Recurrent Bladder Carcinoma1
2RecruitingTreatmentCancers1
2RecruitingTreatmentCancers / Neoplasia / Neoplasms / Tumors1
2RecruitingTreatmentCarcinoma of Buccal Mucosa / Head and Neck Carcinoma / Oral Squamous Cell Carcinoma / Tongue Cancers1
2RecruitingTreatmentDiffuse Intrinsic Pontine Glioma (DIPG)1
2RecruitingTreatmentEGFR Gene Mutations / Non-Small Cell Lung Carcinoma (NSCLC)1
2RecruitingTreatmentEpendymomas / Ewing's Sarcoma (ES) / Gliomas / Medulloblastomas / Neuroectodermal Tumors / Rhabdomyosarcomas / Sarcoma, Osteogenic / Wilms' tumor1
2RecruitingTreatmentEpidermal Growth Factor Receptor / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2RecruitingTreatmentEpithelial Growth Factor Receptor Positive Non-small Cell Lung Cancer / Lung Cancer Non-Small Cell Stage II / Non-small Cell Lung Cancer Stage IIIA / NSCLC Stage II / NSCLC, Stage IIIA1
2RecruitingTreatmentHLRCC / Metastatic Papillary RCC1
2RecruitingTreatmentHead and Neck Carcinoma1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms, Brain1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Small Cell Lung Carcinoma / Thymic Carcinoma1
2RecruitingTreatmentNeoplasms1
2RecruitingTreatmentNon Small Cell Lung Cancer, Oligometastatic1
2RecruitingTreatmentNon-small Cell Lung Cancer Stage IIIA1
2RecruitingTreatmentRare Tumor / Refractory Tumors1
2RecruitingTreatmentRefractory Pediatric AML / Refractory Pediatric Solid Tumors / Relapsed Pediatric AML / Relapsed Pediatric Solid Tumors1
2RecruitingTreatmentRelapsed / Recurrent Germ Cell Tumors1
2RecruitingTreatmentStage III Non-Small Cell Lung Cancer AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v7 / Stage IIIb Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer AJCC v71
2RecruitingTreatmentStage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
2RecruitingTreatmentStage IV Lung Cancer1
2SuspendedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2SuspendedTreatmentMalignant Neoplasm of Pancreas1
2TerminatedTreatmentAdrenal Gland Tumors / Carcinoid Tumors / Multiple Endocrine Neoplasia / Neuroblastomas / Neuroendocrine Tumors / Progressive Neuroendocrine Tumors of pancreatic origin1
2TerminatedTreatmentAdult Brain Tumors1
2TerminatedTreatmentAdult Primary Hepatocellular Carcinoma / Advanced Adult Primary Liver Cancer / Localized Unresectable Adult Primary Liver Cancer1
2TerminatedTreatmentAdvanced Non-Small Cell Lung Cancer1
2TerminatedTreatmentBile Duct Carcinoma / Cholangiocarcinoma of the Extrahepatic Bile Duct / Cholangiocellular Carcinoma / Extrahepatic Bile Duct Cancer / Gallbladder Cancer / Hepatocellular,Carcinoma / Periampullary Adenocarcinoma1
2TerminatedTreatmentCancer, Breast2
2TerminatedTreatmentCancer, Ovarian1
2TerminatedTreatmentEpendymomas1
2TerminatedTreatmentEsophageal Cancers1
2TerminatedTreatmentEsophageal Diseases / Neoplasms, Esophageal1
2TerminatedTreatmentHead and Neck Carcinoma1
2TerminatedTreatmentHepatocellular,Carcinoma1
2TerminatedTreatmentHormone-sensitive Metastatic Breast Cancer1
2TerminatedTreatmentIntraductal Papillary Mucinous Neoplasm of the Pancreas / Recurrent Pancreatic Cancer / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer1
2TerminatedTreatmentLeptomeningeal Carcinomatosis / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)8
2TerminatedTreatmentLung Cancers3
2TerminatedTreatmentLung Cancers / Metastatic Cancers1
2TerminatedTreatmentMalignant Neoplasm of Pancreas9
2TerminatedTreatmentMetastatic Breast Cancer (MBC)1
2TerminatedTreatmentMetastatic Colorectal Cancers2
2TerminatedTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
2TerminatedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2TerminatedTreatmentPolycythemia Vera (PV)1
2TerminatedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2TerminatedTreatmentRecurrent or Refractory Pediatric Ependymoma1
2TerminatedTreatmentSkin Cancers1
2TerminatedTreatmentSquamous Cell Carcinoma (SCC)1
2TerminatedTreatmentStage IA Non-small Cell Lung Cancer / Stage IB Non-small Cell Lung Cancer / Stage IIA Non-small Cell Lung Cancer / Stage IIB Non-small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer1
2TerminatedTreatmentStage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Verrucous Carcinoma of the Larynx / Stage III Verrucous Carcinoma of the Oral Cavity / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx / Stage IV Verrucous Carcinoma of the Larynx / Stage IV Verrucous Carcinoma of the Oral Cavity1
2Unknown StatusDiagnosticLung Cancer Non-Small Cell Cancer (NSCLC)1
2Unknown StatusTreatmentAdenocarcinoma, Bronchiolo-Alveolar / Lung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms, Lung1
2Unknown StatusTreatmentBrain and Central Nervous System Tumors1
2Unknown StatusTreatmentDrug Therapy / Genes, EGFR / Neoplasms, Lung / Non-Small Cell Lung Carcinoma (NSCLC)1
2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)12
2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Metastatic Brain Tumors2
2Unknown StatusTreatmentLung Cancers4
2Unknown StatusTreatmentLung, Carcinoma1
2Unknown StatusTreatmentMetastatic Colorectal Cancers1
2Unknown StatusTreatmentNeuroendocrine Tumors1
2Unknown StatusTreatmentPancreatic Cancer Metastatic1
2WithdrawnTreatmentAdenocarcinoma of the Pancreas1
2WithdrawnTreatmentCancer, Breast1
2WithdrawnTreatmentCancers1
2WithdrawnTreatmentCarcinoma NOS / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2WithdrawnTreatmentLung Cancers / Metastatic Cancers1
2WithdrawnTreatmentMyelodysplastic Syndrome1
2WithdrawnTreatmentPsoriasis1
2WithdrawnTreatmentRecurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2, 3Active Not RecruitingTreatmentEpidermal Growth Factor Receptor / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2, 3Active Not RecruitingTreatmentRecurrent Squamous Cell Lung Carcinoma / Stage IV Squamous Cell Lung Carcinoma1
2, 3RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2, 3RecruitingTreatmentRecurrent Squamous Cell Lung Carcinoma / Stage IV Squamous Cell Lung Carcinoma / Stage IV Squamous Cell Lung Carcinoma AJCC v71
2, 3TerminatedTreatmentHead and Neck Carcinoma / Squamous Cell Carcinoma (SCC)1
2, 3TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3Active Not RecruitingPreventionOral Cancers1
3Active Not RecruitingTreatmentLocally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer1
3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)5
3Active Not RecruitingTreatmentTumors, Solid1
3CompletedTreatmentAdvanced Non-Small Cell Lung Cancer1
3CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
3CompletedTreatmentColorectal Cancers2
3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)16
3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Multiple Brain Metastases1
3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Squamous Non-Small Cell Lung Cancer1
3CompletedTreatmentLung Cancers2
3CompletedTreatmentMalignant Neoplasm of Pancreas4
3CompletedTreatmentMetastatic Colorectal Cancers1
3CompletedTreatmentNon Squamous, Non-small-cell Lung Cancer1
3CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
3CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer5
3CompletedTreatmentStage IV Non-Small Cell Lung Cancer1
3CompletedTreatmentThoracic Neoplasms1
3CompletedTreatmentUnresectable, Metastatic Biliary Tract Carcinoma1
3Enrolling by InvitationTreatmentCancers1
3Enrolling by InvitationTreatmentEGFR Gene Mutations1
3RecruitingTreatmentALK Gene Rearrangement / EGFR Exon 19 Deletion Mutation / EGFR NP_005219.2:p.L858R / Stage IB Non-Small Cell Lung Carcinoma / Stage IB Non-Small Cell Lung Carcinoma AJCC v7 / Stage II Non-Small Cell Lung Cancer AJCC v7 / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIB Non-Small Cell Lung Carcinoma / Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v71
3RecruitingTreatmentEGFR Mutations / Lung Cancer Non-Small Cell Cancer (NSCLC)1
3RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
3RecruitingTreatmentMetastatic Non-Small Cell Lung Cancer1
3RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
3RecruitingTreatmentNon-Squamous Non-Small Cell Lung Cancer1
3RecruitingTreatmentPancreatic Acinar Cell Carcinoma / Pancreatic Ductal Adenocarcinoma / Pancreatic Intraductal Papillary-Mucinous Neoplasm / Stage IA Pancreatic Cancer / Stage IA Pancreatic Cancer AJCC v6 and v7 / Stage IB Pancreatic Cancer / Stage IB Pancreatic Cancer AJCC v6 and v7 / Stage IIA Pancreatic Cancer / Stage IIA Pancreatic Cancer AJCC v6 and v7 / Stage IIB Pancreatic Cancer / Stage IIB Pancreatic Cancer AJCC v6 and v71
3TerminatedTreatmentCarcinoma, Adenosquamous Cell / Carcinoma, Large Cell / Lung Cancer Non-Small Cell Cancer (NSCLC) / Squamous Cell Carcinoma (SCC)1
3TerminatedTreatmentHead and Neck Carcinoma1
3TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
3TerminatedTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
3TerminatedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer / Tumors Metastatic to Brain1
3Unknown StatusNot AvailableLung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms Metastasis1
3Unknown StatusPreventionLung Cancer Non-Small Cell Cancer (NSCLC)1
3Unknown StatusPreventionLung Cancers1
3Unknown StatusTreatmentEsophageal Cancers1
3Unknown StatusTreatmentEsophageal Squamous Carcinoma1
3Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
3Unknown StatusTreatmentLung Cancers1
3Unknown StatusTreatmentMalignant Neoplasm of Pancreas1
3WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
4CompletedTreatmentGastrointestinal Stroma Tumors / Lung Cancer Non-Small Cell Cancer (NSCLC) / Renal-cell Cancer1
4CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)5
4CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Squamous Non-Small Cell Lung Cancer1
4CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer1
4Not Yet RecruitingTreatmentAdenocarcinoma of the Lung1
4RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
4SuspendedTreatmentMetastatic Non-Small Cell Lung Cancer1
4TerminatedTreatmentMalignant Neoplasm of Pancreas1
Not AvailableActive Not RecruitingDiagnosticAdvanced Solid Tumors / Cancers1
Not AvailableActive Not RecruitingTreatmentBrain Cancer1
Not AvailableActive Not RecruitingTreatmentLung Cancers1
Not AvailableActive Not RecruitingTreatmentRecurrent Childhood Brain Tumor1
Not AvailableCompletedNot AvailableLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableCompletedNot AvailableNeoplasms, Head and Neck1
Not AvailableCompletedNot AvailableNon-Squamous Non-Small Cell Lung Cancer1
Not AvailableCompletedNot AvailableNon-Squamous Non-Small Cell Lung Cancer / Nonsquamous Nonsmall Cell Neoplasm of Lung1
Not AvailableCompletedHealth Services ResearchLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableCompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableCompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
Not AvailableRecruitingDiagnosticCancers / High-Grade Gliomas1
Not AvailableRecruitingOtherEGFR Gene Mutations / Non-Small Cell Adenocarcinoma / Tyrosine kinase mutation1
Not AvailableRecruitingPreventionFibrosis / Hepatocellular,Carcinoma / Liver Cirrhosis1
Not AvailableRecruitingTreatmentOligometastatic Lung Adenocarcinoma1
Not AvailableTemporarily Not AvailableNot AvailableLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableTerminatedNot AvailableNon-Squamous Non-Small Cell Lung Cancer1
Not AvailableTerminatedTreatmentCancer, Breast1
Not AvailableUnknown StatusDiagnosticEGFR Mutation Positive Non-small Cell Lung Cancer1
Not AvailableUnknown StatusScreeningLung Cancer Non-Small Cell Cancer (NSCLC)1

Pharmacoeconomics

Manufacturers
  • Osi pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
TabletOral100 mg
TabletOral100 mg/1
TabletOral150 mg
TabletOral150 mg/1
TabletOral25 mg/1
TabletOral25 mg
Tablet, film coatedOral100 mg
Tablet, film coatedOral150 mg
Tablet, film coatedOral25 mg
Prices
Unit descriptionCostUnit
Tarceva 150 mg tablet163.98USD tablet
Tarceva 100 mg tablet144.98USD tablet
Tarceva 25 mg tablet52.78USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2514977No2010-06-222024-02-11Canada
CA2216796No2003-09-022015-06-06Canada
US7087613Yes2001-05-092021-05-09Us
US5747498Yes1999-05-082019-05-08Us
US6900221Yes2001-05-092021-05-09Us
USRE41065Yes1999-05-082019-05-08Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityVery slightly soluble (hydrochloride salt - maximal solubility of approximately 0.4 mg/mL occurs at a pH of approximately 2)Not Available
logP2.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00891 mg/mLALOGPS
logP3.13ALOGPS
logP3.2ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)16.14ChemAxon
pKa (Strongest Basic)4.59ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area74.73 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity107.79 m3·mol-1ChemAxon
Polarizability43.48 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9359
Blood Brain Barrier+0.9376
Caco-2 permeable+0.5737
P-glycoprotein substrateSubstrate0.5982
P-glycoprotein inhibitor IInhibitor0.5958
P-glycoprotein inhibitor IINon-inhibitor0.6169
Renal organic cation transporterNon-inhibitor0.7171
CYP450 2C9 substrateNon-substrate0.7942
CYP450 2D6 substrateNon-substrate0.7611
CYP450 3A4 substrateSubstrate0.5886
CYP450 1A2 substrateInhibitor0.7826
CYP450 2C9 inhibitorNon-inhibitor0.5739
CYP450 2D6 inhibitorNon-inhibitor0.6329
CYP450 2C19 inhibitorInhibitor0.598
CYP450 3A4 inhibitorInhibitor0.7194
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7911
Ames testAMES toxic0.5195
CarcinogenicityNon-carcinogens0.9551
BiodegradationNot ready biodegradable0.9907
Rat acute toxicity2.3958 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8158
hERG inhibition (predictor II)Non-inhibitor0.6776
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazanaphthalenes
Sub Class
Benzodiazines
Direct Parent
Quinazolinamines
Alternative Parents
Aniline and substituted anilines / Aminopyrimidines and derivatives / Alkyl aryl ethers / Imidolactams / Heteroaromatic compounds / Secondary amines / Dialkyl ethers / Azacyclic compounds / Acetylides / Organopnictogen compounds
show 1 more
Substituents
Quinazolinamine / Aniline or substituted anilines / Alkyl aryl ether / Aminopyrimidine / Monocyclic benzene moiety / Pyrimidine / Benzenoid / Imidolactam / Heteroaromatic compound / Dialkyl ether
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
terminal acetylenic compound, quinazolines (CHEBI:114785)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Ubiquitin protein ligase binding
Specific Function
Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TG...
Gene Name
EGFR
Uniprot ID
P00533
Uniprot Name
Epidermal growth factor receptor
Molecular Weight
134276.185 Da
References
  1. Kim TE, Murren JR: Erlotinib OSI/Roche/Genentech. Curr Opin Investig Drugs. 2002 Sep;3(9):1385-95. [PubMed:12498017]
  2. Laird AD, Cherrington JM: Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin Investig Drugs. 2003 Jan;12(1):51-64. [PubMed:12517254]
  3. Delbaldo C, Faivre S, Raymond E: [Epidermal growth factor inhibitors]. Rev Med Interne. 2003 Jun;24(6):372-83. [PubMed:12814826]
  4. Bulgaru AM, Mani S, Goel S, Perez-Soler R: Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase. Expert Rev Anticancer Ther. 2003 Jun;3(3):269-79. [PubMed:12820772]
  5. Akita RW, Sliwkowski MX: Preclinical studies with Erlotinib (Tarceva). Semin Oncol. 2003 Jun;30(3 Suppl 7):15-24. [PubMed:12840797]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism an...
Gene Name
NR1I2
Uniprot ID
O75469
Uniprot Name
Nuclear receptor subfamily 1 group I member 2
Molecular Weight
49761.245 Da
References
  1. Harmsen S, Meijerman I, Beijnen JH, Schellens JH: Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemother Pharmacol. 2009 Jun;64(1):35-43. doi: 10.1007/s00280-008-0842-3. Epub 2008 Oct 7. [PubMed:18839173]
  2. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976]

Enzymes

Details
1. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976]
  2. Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J, Gobburu J, Booth B, Benson K, Leighton J, Hsieh LS, Chidambaram N, Zimmerman P, Pazdur R: Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res. 2005 Sep 15;11(18):6414-21. [PubMed:16166415]
  3. Li J, Zhao M, He P, Hidalgo M, Baker SD: Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7. [PubMed:17575239]
  4. Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, Cagnoni PJ: Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2166-71. [PubMed:16609030]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976]
  2. Li J, Zhao M, He P, Hidalgo M, Baker SD: Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7. [PubMed:17575239]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976]
  2. Lu JF, Eppler SM, Wolf J, Hamilton M, Rakhit A, Bruno R, Lum BL: Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther. 2006 Aug;80(2):136-45. [PubMed:16890575]
  3. Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J, Gobburu J, Booth B, Benson K, Leighton J, Hsieh LS, Chidambaram N, Zimmerman P, Pazdur R: Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res. 2005 Sep 15;11(18):6414-21. [PubMed:16166415]
  4. Li J, Zhao M, He P, Hidalgo M, Baker SD: Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7. [PubMed:17575239]
  5. Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, Cagnoni PJ: Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2166-71. [PubMed:16609030]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976]
  2. Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J, Gobburu J, Booth B, Benson K, Leighton J, Hsieh LS, Chidambaram N, Zimmerman P, Pazdur R: Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res. 2005 Sep 15;11(18):6414-21. [PubMed:16166415]
  3. Li J, Zhao M, He P, Hidalgo M, Baker SD: Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7. [PubMed:17575239]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976]
  2. Li J, Zhao M, He P, Hidalgo M, Baker SD: Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7. [PubMed:17575239]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976]
  2. Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, Cagnoni PJ: Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2166-71. [PubMed:16609030]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1B1
Uniprot ID
Q16678
Uniprot Name
Cytochrome P450 1B1
Molecular Weight
60845.33 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976]
  2. Li J, Zhao M, He P, Hidalgo M, Baker SD: Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7. [PubMed:17575239]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Liu Y, Ramirez J, House L, Ratain MJ: The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation. Eur J Cancer. 2010 Jul;46(11):2097-103. doi: 10.1016/j.ejca.2010.04.022. Epub 2010 May 23. [PubMed:20580994]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7. doi: 10.1111/j.1349-7006.2009.01213.x. Epub 2009 May 12. [PubMed:19493273]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH: Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther. 2008 Aug;7(8):2280-7. doi: 10.1158/1535-7163.MCT-07-2250. [PubMed:18723475]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18